Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Valbiotis SA ( (FR:ALVAL) ) has shared an announcement.
Valbiotis has announced its strategic and financial objectives for the coming years, aiming to achieve significant commercial growth through its range of clinically validated dietary supplements for managing cardio-metabolic disorders. The company plans to reach a revenue of over €25 million by 2027 and €100 million by 2030, with a substantial portion expected from international markets. The strategic plan involves an aggressive commercial deployment in France and harnessing opportunities internationally, supported by a structured supply chain and a dedicated marketing team. This roadmap underlines Valbiotis’ commitment to leveraging its scientific excellence to expand its market presence and meet the growing demand for natural health solutions.
More about Valbiotis SA
Valbiotis SA is a French scientific research laboratory specializing in the commercialization of scientifically validated dietary supplements aimed at preventing metabolic and cardiovascular diseases. The company focuses on clinically tested natural health supplements and has a range of products addressing high cholesterol, prediabetes, type 2 diabetes, metabolic syndrome, hypertension, and liver metabolic diseases. Valbiotis aims to become a leader in the natural health supplements market, addressing significant medical needs with its scientifically backed products.
YTD Price Performance: 12.24%
Average Trading Volume: 1,760
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €24.05M
For a thorough assessment of ALVAL stock, go to TipRanks’ Stock Analysis page.
